Contraceptive methods and ovarian cancer risk among Chinese women: A report from the Shanghai Women's Health Study

International Journal of Cancer

Volumn 137, Issue 3, 2015, Pages 607-614

  Huang, Zhezhou ^a,b   Gao, Yutang ^c   Wen, Wanqing ^b   Li, Honglan ^c   Zheng, Wei ^b   Shu, Xiao Ou ^b   Beeghly Fadiel, Alicia ^b  

^a Shanghai Municipal Center for Disease Control and Prevention   (China)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SHANGHAI CANCER INSTITUTE   (China)

Author keywords

contraceptive; ovarian cancer risk; prospective cohort study

Indexed keywords

ADULT; AGED; ARTICLE; CANCER REGISTRY; CHINESE; COHORT ANALYSIS; CONTRACEPTION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; ORAL CONTRACEPTIVE USE; OVARY CANCER; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; UTERINE TUBE LIGATION; WOMEN'S HEALTH; CHINA; HEALTH SURVEY; MIDDLE AGED; OVARIAN NEOPLASMS; RISK;

ADULT; AGED; CHINA; CONTRACEPTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; RISK; RISK FACTORS;

EID: 84929502569     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29412     Document Type: Article

References (41)

1. Boyle P, Levin B., World cancer report 2008 [Internet]. Lyon, France: International Agency for Research on Cancer (IARC), 2008. Available from: http://www.iarc.fr/en/publications/pdfs-online/wcr/2008/wcr-2008.pdf
2. Chornokur G, Amankwah EK, Schildkraut JM, et al., Global ovarian cancer health disparities. Gynecol Oncol 2013; 129: 258-64.
3. Casagrande JT, Louie EW, Pike MC, et al., "Incessant ovulation" and ovarian cancer. Lancet 1979; 2: 170-3.
4. Fathalla MF,. Incessant ovulation-a factor in ovarian neoplasia? Lancet 1971; 2: 163.
5. Cramer DW, Welch WR,. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983; 71: 717-21.
6. Mohle J, Whittemore A, Pike M, et al., Gonadotropins and ovarian cancer risk. J Natl Cancer Inst 1985; 75: 178-80.
7. Crum CP, Drapkin R, Miron A, et al., The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007; 19: 3-9.
8. Prat J,. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch 2012; 460: 237-49.
9. Erickson BK, Conner MG, Landen CN, Jr,. The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol 2013; 209: 409-14.
10. Nik NN, Vang R, Shih I-M, et al., Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annu Rev Pathol 2014; 9: 27-45.
11. Permuth-Wey J, Sellers TA,. Epidemiology of ovarian cancer. Methods Mol Biol 2009; 472: 413-37.
12. Ness RB, Grisso JA, Vergona R, et al., Oral contraceptives, other methods of contraception, and risk reduction for ovarian cancer. Epidemiology 2001; 12: 307-12.
13. La Vecchia C,. Oral contraceptives and ovarian cancer: an update, 1998-2004. Eur J Cancer Prev 2006; 15: 117-24.
14. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, et al,. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371: 303-14.
15. Kumle M, Weiderpass E, Braaten T, et al., Norwegian-Swedish women's lifestyle and health cohort study. Risk for invasive and borderline epithelial ovarian neoplasias following use of hormonal contraceptives: the Norwegian-Swedish women's lifestyle and health cohort study. Br J Cancer 2004; 90: 1386-91.
16. Tworoger SS, Fairfield KM, Colditz GA, et al., Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol 2007; 166: 894-901.
17. United Nations. World contraceptive use 2011 [Internet]. New York, NY: United Nations, 2011. Available from: http://www.un.org/esa/population/publications/contraceptive2011/contraceptive2011.htm
18. Wang C,. Trends in contraceptive use and determinants of choice in China: 1980-2010. Contraception 2012; 85: 570-9.
19. Zheng W, Chow W-H, Yang G, et al., The Shanghai Women's Health Study: rationale, study design, and baseline characteristics. Am J Epidemiol 2005; 162: 1123-31.
20. Risch HA, Weiss NS, Lyon JL, et al., Events of reproductive life and the incidence of epithelial ovarian cancer. Am J Epidemiol 1983; 117: 128-39.
21. Wang C,. History of the Chinese family planning program: 1970-2010. Contraception 2012; 85: 563-9.
22. Zhan G, Ling L, Ying L, et al., Regional economic levels and adverse events linked to intrauterine devices. J Evid Based Med 2011; 4: 8-14.
23. Huang R-F, Liu X-Q, Chen J-P, et al., Removal rate and service time of intrauterine devices among 2054 peri- or postmenopausal women. Reprod Contracept 2014; 34: 41-5.
24. Miao Q, Kong B-H,. [A case-control study on etiology of epithelial ovarian cancer in Shandong province]. Ai Zheng Aizheng Chin J Cancer 2006; 25: 871-5.
25. Zhang G, Jiang S, Zhang F,. [Influence factors in etiology of epithelial ovarian cancer]. Zhonghua Fu Chan Ke Za Zhi 1996; 31: 357-60.
26. Shu XO, Brinton LA, Gao YT, et al., Population-based case-control study of ovarian cancer in Shanghai. Cancer Res 1989; 49: 3670-4.
27. Le D-C, Kubo T, Fujino Y, et al., Reproductive factors in relation to ovarian cancer: a case-control study in Northern Vietnam. Contraception 2012; 86: 494-9.
28. Dorjgochoo T, Shu X-O, Li H-L, et al., Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006. Int J Cancer 2009; 124: 2442-9.
29. WHO. Mechanism of action, safety and efficacy of intrauterine devices. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1987; 753: 1-91.
30. Kaufman J,. The cost of IUD failure in China. Stud Fam Plann 1993; 24: 194-6.
31. Sonfield A,. Popularity disparity: attitudes about the IUD in Europe and the United States. Guttmacher Policy Rev 2007; 10: 19-24.
32. Macciò A, Madeddu C,. Inflammation and ovarian cancer. Cytokine 2012; 58: 133-47.
33. Lee NC, Rubin GL, Ory HW, et al., Type of intrauterine device and the risk of pelvic inflammatory disease. Obstet Gynecol 1983; 62: 1-6.
34. Bilian X,. Chinese experience with intrauterine devices. Contraception 2007; 75: S31-4.
35. Bosetti C, Negri E, Trichopoulos D, et al., Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer 2002; 102: 262-5.
36. Siskind V, Green A, Bain C, et al., Beyond ovulation: oral contraceptives and epithelial ovarian cancer. Epidemiology 2000; 11: 106-10.
37. Chen Y, Wu PC, Lang JH, et al., Risk factors for epithelial ovarian cancer in Beijing, China. Int J Epidemiol 1992; 21: 23-9.
38. Pasalich M, Su D, Binns CW, et al., Reproductive factors for ovarian cancer in Southern Chinese women. J Gynecol Oncol 2013; 24: 135-40.
39. Sieh W, Salvador S, McGuire V, et al., Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int J Epidemiol 2013; 42: 579-89.
40. Cibula D, Widschwendter M, Májek O, et al., Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update 2011; 17: 55-67.
41. Ferlay J, Shin H, Bray F, et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.